ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares

Key Points

• SVP Thomas Andrew Rowland sold 4,772 shares on March 11 at an average price of $74.91 for total proceeds of $357,470.52, trimming his stake by 10.97% to 38,730 shares valued at about $2.90M.
• ANIP stock closed at $70.49 (down $2.00) on volume of 517,923 versus an average of 360,579; the firm has a market cap of ~$1.58B, a P/E of 20.98, and a 52-week range of $56.71–$99.50.
• Analyst sentiment is broadly positive with six Buys and three Holds for an average rating of "Moderate Buy" and an average price target of $103.43, including Guggenheim's $124 target and Barclays' $100 target.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Thomas Andrew Rowland sold 4,772 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the sale, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded down $2.00 during trading hours on Friday, reaching $70.49. The stock had a trading volume of 517,923 shares, compared to its average volume of 360,579. The firm has a market capitalization of $1.58 billion, a PE ratio of 20.98 and a beta of 0.52. The firm has a 50-day simple moving average of $79.12 and a 200-day simple moving average of $85.35. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $28,000. Hantz Financial Services Inc. boosted its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. grew its holdings in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock worth $39,000 after acquiring an additional 400 shares during the period. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $48,000. Finally, State of Wyoming acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on ANIP. Guggenheim boosted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Weiss Ratings reiterated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 price target for the company. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.